Current Report Filing (8-k)
May 11 2023 - 5:21PM
Edgar (US Regulatory)
0001611747
false
00000
00-0000000
0001611747
2023-05-10
2023-05-10
0001611747
BVXV:AmericanDepositarySharesEachRepresenting400OrdinarySharesNoParValueMember
2023-05-10
2023-05-10
0001611747
BVXV:OrdinarySharesNoParValueMember
2023-05-10
2023-05-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May
10, 2023
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of registrant as specified in its charter)
Israel |
|
001-37353 |
|
Not Applicable |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification Number) |
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive offices, including
zip code)
(+972) 8-930-2529
(+972) 8-930-2531 (facsimile)
Registrant’s telephone number, including area
code:
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
American Depositary Shares, each representing 400 Ordinary Shares, no par value |
|
BVXV |
|
Nasdaq Capital Market |
|
|
|
|
|
Ordinary Shares, no par value |
|
|
|
Nasdaq Capital Market* |
* |
Not for trading; only in connection with the registration of American Depositary Shares. |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain
Officers
On May 10, 2023, Mr. George
H. Lowell submitted to the board of directors (the “Board”) of BiondVax Pharmaceuticals Ltd. (the “Company”) his
resignation from his position as a member of the Board, effective May 12, 2023. Mr. Lowell, who had served as a Board member since 2008,
did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or
practices.
Mr. Lowell will remain on
the Company’s Scientific Advisory board (the “Advisory Board”) and will begin serving as a liaison between the Advisory
Board and the Board. The Company and Mr. Lowell are currently in discussions as to Mr. Lowell’s compensation for his continuing
role on the Advisory Board and his new role as liaison between the Advisory and the Board.
Mr. Mark Germain, Chairman
of the Board, commented, “On behalf of the entire Board, I thank George for the valuable contributions he has provided as a Board
member for the past 15 years. We are pleased that he will continue to actively serve on BiondVax’s Scientific Advisory Board.”
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 11, 2023 |
BiondVax Pharmaceuticals Ltd. |
|
|
|
|
By: |
/s/ Amir Reichman |
|
|
Amir Reichman |
|
|
Chief Executive Officer |
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024